(Reuters) -Moderna said on Thursday its next-generation COVID-19 vaccine candidate met its main goal in a late-stage study by showing vaccine efficacy that was non-inferior compared with the company’s commercial shot.
The company has been working on multiple new messenger RNA vaccines, including the recently approved RSV vaccine, mRESVIA, and other experimental shots, to tackle the waning sales of its current COVID vaccine that is sold under the brand Spikevax.
The next-generation COVID shot was being tested in over 11,000 people aged 12 years and older. In adults, it showed superiority in vaccine efficacy to Spikevax, the company said.
The company added that it will engage with regulators on the next steps for the next-generation COVID vaccine.
The new COVID vaccine is also being tested as a combination shot with Moderna’s flu shot. On Monday, the company said the combination vaccine generated a stronger immune response in adults aged 50 and over when compared to separate shots against the COVID and flu viruses in a late-stage trial.
(Reporting by Leroy Leo in Bengaluru; Editing by Maju Samuel)
Comments